Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
References (7)
- Joye F, Orrillard M, Marion F, et al. Intoxication sévère probable par olanzapine (Zyprexa). Effet bénéfique du glucagon. [Severe intoxication likely from olanzapine (Zyprexa). beneficial effect of glucagon]. Ann Fr Anesth Reanim. 1999;18(6):686–690. PubMed CrossRef
- Bever KA, Perry PJ. Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. Am J Health Syst Pharm. 1998;55(10):1003–1016. PubMed CrossRef
- Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51–68. PubMed CrossRef
- Markowitz JS, DeVane CL, Boulton DW, et al. Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine. J Clin Pharmacol. 2002;42(1):104–106. PubMed CrossRef
- Thomas K, Saadabadi A. Olanzapine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; January 2022. Accessed May 2, 2022. https://www.ncbi.nlm.nih.gov/books/NBK532903/
- Sidhu S, Marine JE. Evaluating and managing bradycardia. Trends Cardiovasc Med. 2020;30(5):265–272. PubMed CrossRef
- Citrome L, McEvoy JP, Todtenkopf MS, et al. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019;15:2559–2569. PubMed CrossRef
Please sign in or purchase this PDF for $40.